Welcome to our dedicated page for Ngm Biopharmaceuticals news (Ticker: NGM), a resource for investors and traders seeking the latest updates and insights on Ngm Biopharmaceuticals stock.
NGM Biopharmaceuticals Inc. develops biotechnology drug candidates through a biology-centric discovery engine that combines disease biology and protein engineering. Company news has centered on clinical and regulatory updates for its pipeline, including NGM707, a dual ILT2/ILT4 antagonist antibody evaluated in advanced or metastatic solid tumors, and aldafermin development in primary sclerosing cholangitis and other rare-disease strategy discussions.
Recurring updates also include oncology conference presentations, clinical-data posters, operating and financial results, governance matters, capital-structure disclosures, shareholder voting matters and material agreements. Corporate-action news includes the completed cash tender offer by an affiliate of The Column Group for shares of NGM Bio not already held by affiliates and certain other stockholders.
Xaira Therapeutics has appointed Jeff Jonker as President and Chief Operating Officer, reporting to CEO Marc Tessier-Lavigne. Jonker, a biotech industry veteran with over two decades of leadership experience, will help scale Xaira's AI-enabled drug discovery platform and oversee operational functions.
Jonker's experience includes serving as CEO of Belharra Therapeutics and Ambys Medicines, and as President of NGM Biopharmaceuticals (NASDAQ: NGM). At NGM, he expanded the therapeutic pipeline and formed a strategic partnership with Merck. The appointment comes as Xaira advances its AI-driven drug discovery initiatives, recently publishing X‑Atlas/Orion, the largest publicly available genome-wide Perturb‑seq dataset.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.